LivaNova PLC
General ticker "LIVN" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $3.2B (TTM average)
LivaNova PLC follows the US Stock Market performance with the rate: 61.4%.
Estimated limits based on current volatility of 1.8%: low 79.00$, high 81.97$
Factors to consider:
- Total employees count: 3300 (+13.8%) as of 2025
- US accounted for 57.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Geopolitical risks, Cybersecurity threats, Regulatory and compliance, Market competition, Product recalls
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [55.60$, 86.91$]
- 2026-12-31 to 2027-12-31 estimated range: [53.25$, 84.54$]
Financial Metrics affecting the LIVN estimates:
- Negative: with PPE of 16.1 at the end of fiscal year the price was high
- Positive: 7.57 < Operating profit margin, % of 14.43
- Positive: 6.62 < Operating cash flow per share per price, % of 7.45
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 1.44 <= 3.34
- Positive: Industry inventory ratio change (median), % of 0.25 <= 0.28
- Positive: 42.57 < Shareholder equity ratio, % of 46.05 <= 64.23
Short-term LIVN quotes
Long-term LIVN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,153.55MM | $1,220.39MM | $1,382.15MM |
| Operating Expenses | $1,222.04MM | $1,091.34MM | $1,182.76MM |
| Operating Income | $-68.50MM | $129.05MM | $199.39MM |
| Non-Operating Income | $-12.83MM | $-40.74MM | $-420.17MM |
| Interest Expense | $58.85MM | $63.07MM | $49.29MM |
| R&D Expense | $193.82MM | $182.51MM | $185.76MM |
| Income(Loss) | $-81.33MM | $88.31MM | $-220.78MM |
| Taxes | $-98.88MM | $25.06MM | $21.64MM |
| Other Income(Loss) | $-0.10MM | $-0.02MM | $-0.05MM |
| Net Income(Loss)* | $17.55MM | $63.23MM | $-242.50MM |
| Stockholders Equity | $1,277.63MM | $1,320.26MM | $1,199.99MM |
| Inventory | $147.89MM | $147.57MM | $164.70MM |
| Assets | $2,429.56MM | $2,506.39MM | $2,606.05MM |
| Operating Cash Flow | $74.91MM | $183.04MM | $254.34MM |
| Capital expenditure | $34.98MM | $47.11MM | $81.10MM |
| Investing Cash Flow | $-40.33MM | $-48.16MM | $-72.91MM |
| Financing Cash Flow | $21.48MM | $18.55MM | $-285.66MM |
| Earnings Per Share** | $0.33 | $1.17 | $-4.45 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.